D70.1

Agranulocytosis secondary to cancer chemotherapy

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC ESRD V24

HCC47

Disorders of Immunity

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

This code · D70.1

Use additional

code for adverse effect, if applicable, to identify drug (T45.1X5)

Code also

underlying neoplasm

Inherited from D70Neutropenia

Includes

agranulocytosis decreased absolute neurophile count (ANC)

Excludes 1

neutropenic splenomegaly (D73.81) transient neonatal neutropenia (P61.5)

Use additional

code for any associated: fever (R50.81)

Code also

, if applicable, mucositis (J34.81, K12.3-, K92.81, N76.81)

Inherited from chapter 3Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

Excludes 2

autoimmune disease (systemic) NOS (M35.9) certain conditions originating in the perinatal period (P00-P96) complications of pregnancy, childbirth and the puerperium (O00-O9A) congenital malformations, deformations and chromosomal abnormalities (Q00-Q99) endocrine, nutritional and metabolic diseases (E00-E88) human immunodeficiency virus [HIV] disease (B20) injury, poisoning and certain other consequences of external causes (S00-T88) neoplasms (C00-D49) symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)

Official Guidelines for D70.1

FY 2026 ›

I.C.3Chapter-specific guidanceChapter 3: Disease of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)

Find D70.1 in the alphabetic index

8 index paths lead to this code